202 related articles for article (PubMed ID: 33675070)
1. Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
Chen J; Chen YJ; Jiang N; Xu JL; Liang ZM; Bai MJ; Xing YF; Liu Z; Wu XY; Li X
Oncologist; 2021 Aug; 26(8):e1434-e1444. PubMed ID: 33675070
[TBL] [Abstract][Full Text] [Related]
2. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
3. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
4. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Serum Apolipoprotein B to Apolipoprotein A-I Ratio in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.
Liu MM; Chen ZH; Zhao LY; Zhao JY; Rong DL; Ma XK; Ruan DY; Lin JX; Qi JJ; Hu PS; Wen JY; Chen J; Lin Q; Wu XY; Wei L; Dong M
Oncol Res Treat; 2021; 44(9):450-468. PubMed ID: 34380137
[TBL] [Abstract][Full Text] [Related]
6. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
[TBL] [Abstract][Full Text] [Related]
7. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
8. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
10. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy.
Chen ZH; Zhang XP; Cai XR; Xie SD; Liu MM; Lin JX; Ma XK; Chen J; Lin Q; Dong M; Wu XY; Wen JY; Xu RH
J Cancer; 2018; 9(19):3467-3478. PubMed ID: 30310503
[No Abstract] [Full Text] [Related]
12. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
[TBL] [Abstract][Full Text] [Related]
13. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
14. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
[TBL] [Abstract][Full Text] [Related]
15. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Liu C; Li L; Lu WS; Du H; Yan LN; Wen TF; Wei WR; Jiang L; Xu MQ
BMC Cancer; 2018 Feb; 18(1):216. PubMed ID: 29466970
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
17. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study.
Long J; Zheng JS; Sun B; Lu N
Hepatol Int; 2016 Jan; 10(1):175-84. PubMed ID: 26742761
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
